Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Attenuate Newcastle disease virus by codon modification of the glycoproteins and phosphoprotein genes.

Wang W, Cheng X, Buske PJ, Suzich JA, Jin H.

Virology. 2019 Feb;528:144-151. doi: 10.1016/j.virol.2018.12.017. Epub 2019 Jan 5.

PMID:
30616204
2.

Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897.

Zhu Q, Lu B, McTamney P, Palaszynski S, Diallo S, Ren K, Ulbrandt ND, Kallewaard N, Wang W, Fernandes F, Wong S, Svabek C, Moldt B, Esser MT, Jing H, Suzich JA.

J Infect Dis. 2018 Jul 13;218(4):572-580. doi: 10.1093/infdis/jiy189.

PMID:
29617879
3.

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.

Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, Moldt B, Khan A, Svabek C, McAuliffe JM, Wrapp D, Patel NK, Cook KE, Richter BWM, Ryan PC, Yuan AQ, Suzich JA.

Sci Transl Med. 2017 May 3;9(388). pii: eaaj1928. doi: 10.1126/scitranslmed.aaj1928.

PMID:
28469033
4.

Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes.

Kallewaard NL, Corti D, Collins PJ, Neu U, McAuliffe JM, Benjamin E, Wachter-Rosati L, Palmer-Hill FJ, Yuan AQ, Walker PA, Vorlaender MK, Bianchi S, Guarino B, De Marco A, Vanzetta F, Agatic G, Foglierini M, Pinna D, Fernandez-Rodriguez B, Fruehwirth A, Silacci C, Ogrodowicz RW, Martin SR, Sallusto F, Suzich JA, Lanzavecchia A, Zhu Q, Gamblin SJ, Skehel JJ.

Cell. 2016 Jul 28;166(3):596-608. doi: 10.1016/j.cell.2016.05.073. Epub 2016 Jul 21.

5.

A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.

DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK.

Sci Transl Med. 2014 Nov 12;6(262):262ra155. doi: 10.1126/scitranslmed.3009655.

6.

A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head.

Benjamin E, Wang W, McAuliffe JM, Palmer-Hill FJ, Kallewaard NL, Chen Z, Suzich JA, Blair WS, Jin H, Zhu Q.

J Virol. 2014 Jun;88(12):6743-50. doi: 10.1128/JVI.03562-13. Epub 2014 Apr 2.

7.

Potential for palivizumab interference with commercially available antibody-antigen based respiratory syncytial virus diagnostic assays.

Deming DJ, Patel N, McCarthy MP, Mishra L, Shapiro AM, Suzich JA.

Pediatr Infect Dis J. 2013 Oct;32(10):1144-6. doi: 10.1097/INF.0b013e31829561dd.

PMID:
23584584
8.

Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.

DiGiandomenico A, Warrener P, Hamilton M, Guillard S, Ravn P, Minter R, Camara MM, Venkatraman V, Macgill RS, Lin J, Wang Q, Keller AE, Bonnell JC, Tomich M, Jermutus L, McCarthy MP, Melnick DA, Suzich JA, Stover CK.

J Exp Med. 2012 Jul 2;209(7):1273-87. doi: 10.1084/jem.20120033. Epub 2012 Jun 25.

9.

Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab.

Zhu Q, Patel NK, McAuliffe JM, Zhu W, Wachter L, McCarthy MP, Suzich JA.

J Infect Dis. 2012 Feb 15;205(4):635-8. doi: 10.1093/infdis/jir790. Epub 2011 Dec 19.

PMID:
22184728
10.

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.

Zhu Q, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, Liang B, Su L, Zhu W, Wachter L, Wilson S, MacGill RS, Krishnan S, McCarthy MP, Losonsky GA, Suzich JA.

J Infect Dis. 2011 Mar 1;203(5):674-82. doi: 10.1093/infdis/jiq100. Epub 2011 Jan 5.

11.

Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo.

Ulbrandt ND, Ji H, Patel NK, Riggs JM, Brewah YA, Ready S, Donacki NE, Folliot K, Barnes AS, Senthil K, Wilson S, Chen M, Clarke L, MacPhail M, Li J, Woods RM, Coelingh K, Reed JL, McCarthy MP, Pfarr DS, Osterhaus AD, Fouchier RA, Kiener PA, Suzich JA.

J Virol. 2006 Aug;80(16):7799-806.

12.

Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies.

Damschroder MM, Kozhich AA, Woods RM, Cheng L, Mullikin BA, Wilson SD, Ulbrandt ND, Bachy CM, Wu H, Suzich JA, Kiener PA, Dall'Acqua WF, White WI.

Mol Immunol. 2004 Aug;41(10):985-1000.

PMID:
15302161
13.

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.

DeVincenzo JP, Hall CB, Kimberlin DW, Sánchez PJ, Rodriguez WJ, Jantausch BA, Corey L, Kahn JS, Englund JA, Suzich JA, Palmer-Hill FJ, Branco L, Johnson S, Patel NK, Piazza FM.

J Infect Dis. 2004 Sep 1;190(5):975-8. Epub 2004 Jul 27.

PMID:
15295704
14.

A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.

Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M, White WI, Balsley J, Reichman RC.

J Infect Dis. 2001 May 15;183(10):1485-93. Epub 2001 Apr 24.

PMID:
11319684
15.

Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies.

Rose RC, Lane C, Wilson S, Suzich JA, Rybicki E, Williamson AL.

Vaccine. 1999 Apr 23;17(17):2129-35.

PMID:
10367945
16.

Characterization of a major neutralizing epitope on human papillomavirus type 16 L1.

White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim SJ, Hewitt LA, Goldman DM, Burke SJ, Jenson AB, Koenig S, Suzich JA.

J Virol. 1999 Jun;73(6):4882-9.

17.

Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL.

J Virol. 1998 Jul;72(7):6151-4.

18.

In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16.

White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA.

J Virol. 1998 Feb;72(2):959-64.

19.

Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro.

McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA.

J Virol. 1998 Jan;72(1):32-41.

20.

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R.

Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11553-7.

21.

Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes.

Suzich JA, Tamura JK, Palmer-Hill F, Warrener P, Grakoui A, Rice CM, Feinstone SM, Collett MS.

J Virol. 1993 Oct;67(10):6152-8.

22.

Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein.

Koenig S, Fuerst TR, Wood LV, Woods RM, Suzich JA, Jones GM, de la Cruz VF, Davey RT Jr, Venkatesan S, Moss B, et al.

J Immunol. 1990 Jul 1;145(1):127-35.

PMID:
1694201
23.
24.

Rift Valley fever virus M segment: phlebovirus expression strategy and protein glycosylation.

Kakach LT, Suzich JA, Collett MS.

Virology. 1989 Jun;170(2):505-10.

PMID:
2728348
25.

Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins.

Schmaljohn CS, Parker MD, Ennis WH, Dalrymple JM, Collett MS, Suzich JA, Schmaljohn AL.

Virology. 1989 May;170(1):184-92.

PMID:
2655274
26.
27.

3-Deoxy-d-arabino-Heptulosonate 7-Phosphate Synthase from Potato Tuber (Solanum tuberosum L.).

Pinto JE, Suzich JA, Herrmann KM.

Plant Physiol. 1986 Dec;82(4):1040-4.

28.
29.

Regulation of the shikimate pathway of carrot cells in suspension culture.

Suzich JA, Ranjeva R, Hasegawa PM, Herrmann KM.

Plant Physiol. 1984 Jun;75(2):369-71.

Supplemental Content

Loading ...
Support Center